Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI

NCT02342353 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02342353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02342353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Terminated
Start date
May 18, 2015
Completion date
February 6, 2018
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, non-small cell lung cancer, nonsmall cell lung cancer